{
  "ticker": "ACW",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02958565",
  "id": "02958565",
  "pages": 21,
  "price_sensitive": false,
  "date": "20250616",
  "time": "0900",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250616/pdf/06krz8s3r06xc6.pdf",
  "summary": "**Key Material Information Extracted:**  \n\n- **Corporate Presentation at BIO 2025**:  \n  - Management (CCO and CMO) engaging with investors and potential partners to discuss **Xanamem\u00ae** (lead asset) and ongoing **Phase 2b/3 Alzheimer\u2019s trial**.  \n  - Focus on **partnering opportunities** for Alzheimer\u2019s and depression programs.  \n\n- **XanaMIA Phase 2b/3 Alzheimer\u2019s Trial**:  \n  - **Interim results expected Q4 2025** (n=100 at 24 weeks), **final results Q4 2026** (n=220 at 36 weeks).  \n  - **Primary endpoint**: CDR-SB (Clinical Dementia Rating scale).  \n  - Targets **mild-to-moderate Alzheimer\u2019s patients** with elevated pTau181 biomarker.  \n\n- **Depression Program (XanaCIDD Phase 2a)**:  \n  - **Positive results reported August 2024** \u2013 statistically significant improvement in depression symptoms (MADRS scale).  \n  - Potential for **combination therapy** (low drug interaction risk).  \n\n- **Catalysts**:  \n  - **Near-term**: BIO 2025 partner discussions (June 16\u201319).  \n  - **Mid-term**: Interim Alzheimer\u2019s data (Q4 2025), funding strategy for next depression trial.  \n\n- **Commercial Potential**:  \n  - Alzheimer\u2019s market: ~$20B by 2030; depression market: ~$20B currently.  \n  - **Patent protection**: Composition of matter to 2031 (extendable to 2036).  \n\n*Omitted: Background on mechanism, historical data, non-material pipeline details.*",
  "usage": {
    "prompt_tokens": 5003,
    "completion_tokens": 361,
    "total_tokens": 5364,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-15T23:14:03.623554"
}